美国食品药品监督管理局（FDA）拒绝批准Atara Biotherapeutics的血癌治疗方案，导致该公司股价在盘前交易时段大幅下挫55%。这一监管决定对该公司致力于推进肿瘤免疫疗法开发的努力构成重大打击。
美国食品药品监督管理局（FDA）拒绝批准Atara Biotherapeutics的血癌治疗方案，导致该公司股价在盘前交易时段大幅下挫55%。这一监管决定对该公司致力于推进肿瘤免疫疗法开发的努力构成重大打击。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.